Details

Autor(en) / Beteiligte

• Baven‐Pronk, A. M. C.
• Coenraad, M. J.
• van Buuren, H. R.
• de Man, R. A.
• van Erpecum, K. J.
• Lamers, M. M. H.
• Drenth, J. P. H.
• van den Berg, A. P.
• Beuers, U. H.
• den Ouden, J.
• Koek, G. H.
• van Nieuwkerk, C. M. J.
• Bouma, G.
• Brouwer, J. T.
• van Hoek, B.

Titel

The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

Ist Teil von

• Alimentary pharmacology & therapeutics, 2011-08, Vol.34 (3), p.335-343

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2011

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• Aliment Pharmacol Ther 2011; 34: 335–343 Summary Background  Treatment failure occurs in 20% of autoimmune hepatitis patients on prednisolone and azathioprine (AZA). There is no established second line treatment. Aim  To assess the efficacy of mycophenolate mofetil as second line treatment after AZA‐intolerance or AZA‐nonresponse in autoimmune hepatitis and overlap syndromes. Methods  Consecutive patients from the Dutch Autoimmune Hepatitis Group cohort, consisting of 661 patients, with autoimmune hepatitis or overlap syndromes, AZA‐intolerance or AZA‐nonresponse and past or present use of mycophenolate mofetil were included. Primary endpoint of mycophenolate mofetil treatment was biochemical remission. Secondary endpoints were biochemical response (without remission), treatment failure and prevention of disease progression. Results  Forty‐five patients treated with mycophenolate mofetil were included. In autoimmune hepatitis remission or response was achieved in 13% and 27% in the AZA‐nonresponse group compared to 67% and 0% in the AZA‐intolerance group (P = 0.008). In overlap‐syndromes remission or response was reached in 57% and 14% in the AZA‐nonresponse group and 63% and 25% of the AZA‐intolerance group (N.S.); 33% had side effects and 13% discontinued mycophenolate mofetil. Overall 38% had treatment failure; this was 60% in the autoimmune hepatitis AZA‐nonresponse group. Decompensated liver cirrhosis, liver transplantations and death were only seen in the autoimmune hepatitis AZA‐nonresponse group (P < 0.001). Conclusions  Mycophenolate mofetil induced response or remission in a majority of patients with autoimmune hepatitis and azathioprine‐intolerance and with overlap syndromes, irrespective of intolerance or nonresponse for azathioprine. In autoimmune hepatitis with azathioprine nonresponse mycophenolate mofetil is less often effective.